Licensing · MENA · Announced 9 Oct 2026
Lotus Pharmaceutical → ADCAN Pharma
Licensing deal between Lotus Pharmaceutical (Taiwan) and ADCAN Pharma (United Arab Emirates), announced 9 Oct 2026.
Parties: Lotus Pharmaceutical (Taiwan) → ADCAN PHARMA (United Arab Emirates)
- Deal type
- Licensing
- Value
- Not stated
- Territory
- UAE, Saudi Arabia, Iraq, Libya and Gulf region (explicit per ADCAN CEO statement — notably wider than the other CPHI deals)
- Therapeutic area
- Oncology
- Asset
- (1) Licensing agreement for a first complex generic asset (molecule undisclosed); (2) Memorandum of Understanding for a broader strategic partnership to expand a complex specialty generics portfolio across MENA
- Announced
- 9 Oct 2026
Our analysis
Why this matters
Two verified details make this the most structurally interesting of the ADCAN deals this month
First, the format: one named complex generic licensed now, with the broader relationship parked in an MoU — ADCAN pays only for what it can execute immediately while keeping the full Lotus relationship warm.
The full analysis is free to read with a work email on this page.
Source: ADCAN MEDIA